13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
OncView™ Podcast: NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
This special episode of “Oncology Peer Review On-The-Go” features Lee Schwartzberg, MD, FACP discussing treatment patterns in HR-positive breast cancer with.
Treatment Limitations in HR+ Breast Cancer
Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.
Current Recommendations for Genomic Testing in HR+ Breast Cancer
Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.
Integration of Genomic Testing into NCCN Guidelines
Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.
Appropriateness for Genomic Testing in HR+ Breast Cancer
Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.
Role of Genomic Testing in HR Positive Breast Cancer
Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.
Molecular Biomarkers for HR+ Breast Cancer
An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.
Extended Adjuvant Therapy for HR+ Breast Cancer
The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.